1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Research on China Monoclonal Antibody (McAB) Industry, 2014

Research on China Monoclonal Antibody (McAB) Industry, 2014

  • July 2014
  • -
  • Huidian Research
  • -
  • 60 pages



Please note: The report is Chinese version. It will provide the English version in two business days.

Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China’s monoclonal antibody industry.

Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal antibody agents, which have achieved results in 2013. Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have applied for clinical research of monoclonal antibody agents. And Walvax Biotechnology Co., Ltd even made a huge investment in purchasing Genor Biopharma Co., Ltd, attempting to establish a large biological strategy. Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the overall innovation is still insufficient, and the market is represented by monoclonal antibody agents and biological analogue that have submitted applications, few imitated drugs, and innovative medicines are rare and precious things, mainly on account of high risks and long-time cycle.

Due to late state, China’s strength on research and development will be still vulnerable within future three to five years, so it has to open the market preliminarily by depending on generic drugs. In 2013, the market size was CNY 3.8 billion around, up 30% year-on-year; product categories and sales volume were far less than that of European and American countries.

According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA), China will see four to six monoclonal antibody agents by 2016, such as Trastuzumab and Rituximab. And it is expected by 2020, six to ten monoclonal antibody agents will be listed in market, and some of which are independently researched drugs. Huidian Research believes that China’s monoclonal antibody market will embrace its first climax from 2017 to 2020.

Table Of Contents

Research on China Monoclonal Antibody (McAB) Industry, 2014
1. Overview of Monoclonal Antibody
1.1 Definition and Characteristics
1.2 Preparation Process of Monoclonal Antibody
1.3 Classification
1.4 Mechanism of Action
1.5 Key Technology

2. Operation Environment of China's Monoclonal Antibody Industry
2.1 Analysis of Economic Environment
2.2 Policy Analysis
2.2.1 Monoclonal Antibody Industry Ranks as a Strategic Emerging Industry
2.2.2 NCCN Guidance Supports Monoclonal Antibody Agents; McAB Agents are Included into Local Health Insurance

3. Current Situation and Tendencies of Worldwide Monoclonal Antibody Industry
3.1 Development History Overview of International Monoclonal Antibody Market
3.2 Monoclonal Antibody Agents Listing in Market
3.3 Global Key Enterprises Devoting to Developing Monoclonal Antibody Agents
3.4 Powerful Growth Momentum of Global Antibody Market
3.5 Development Tendency and Outlook of Global Monoclonal Antibody Agents
3.5.1 Develop Monoclonal Antibody Aiming at New Target Spots
3.5.2 Diversified Research and Development on Monoclonal Antibody
3.5.3 Antibody-Drug-Conjugates (ADCs) as a New Research Hotspot and Development Direction
3.5.4 First Monoclonal Antibody Biological Analogue Approved in European and American Market

4. Operation Situation of China's Monoclonal Antibody Industry
4.1 Small Market Size
4.2 Listing Situation of Monoclonal Antibody Agents
4.3 Comparison of Research Progress between China and Foreign Countries
4.3.1 China's Research Progress on Monoclonal Antibody
4.3.2 Differences of New Rand D Ability and Industrialization between China and Foreign Countries
4.4 The First Climax of Monoclonal Antibody: 2017 to 2020

5. China's Key Monoclonal Antibody Agent Enterprises
5.1 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ)
5.1.1 Company Profile
5.1.2 Business Condition
5.1.3 The Generic Drug of Trastuzumab - Sai Pu Ting Approved for Clinical Use
5.2 Biotech Pharmaceuticals Co., Ltd.
5.2.1 Company Profile
5.2.2 Business Condition
5.2.3 Production Process
5.3 Chengdu Huasun Biotechnology Co., Ltd.
5.3.1 Company Profile
5.3.2 Representative Products
5.3.3 Business Condition
5.4 Zhejiang HISUN Pharmaceutical Co., Ltd.
5.4.1 Company Profile
5.4.2 Business Condition
5.4.3 Progress of R and D
5.5 Shanghai Bio Pharmaceutical Co., Ltd.
5.5.1 Company Profile
5.5.2 Business Condition
5.5.3 Progress of R and D

6. Huge Growth Potential and Development Opportunities of China Monoclonal Antibody Market in the Future
6.1 Enormous China's Market Space and Potential Medical Demand not Get Satisfied
6.2 Late-Mover Advantage and Unique Opportunity of China Monoclonal Antibody Market


Companies Mentioned
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ)
Biotech Pharmaceuticals Co., Ltd.
Chengdu Huasun Biotechnology Co., Ltd.
Zhejiang HISUN Pharmaceutical Co., Ltd.
Shanghai Bio Pharmaceutical Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a small-molecule medicine which has to be administered orally and has been proven to be effective in blocking ...

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.